| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesenchymal Stem Cells | 26 | 2015 | 165 | 4.030 |
Why?
|
| Ovarian Neoplasms | 8 | 2013 | 84 | 1.700 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 9 | 2012 | 73 | 1.370 |
Why?
|
| Stromal Cells | 5 | 2016 | 66 | 1.230 |
Why?
|
| Neoplasms | 10 | 2018 | 754 | 1.140 |
Why?
|
| Cell Movement | 9 | 2016 | 167 | 1.050 |
Why?
|
| Bone Marrow Cells | 8 | 2013 | 114 | 0.970 |
Why?
|
| Mice | 39 | 2020 | 2571 | 0.960 |
Why?
|
| Fibroblasts | 6 | 2013 | 119 | 0.930 |
Why?
|
| Animals | 53 | 2020 | 8199 | 0.880 |
Why?
|
| Cell Line, Tumor | 26 | 2020 | 729 | 0.870 |
Why?
|
| Breast Neoplasms | 10 | 2019 | 762 | 0.850 |
Why?
|
| Cell Differentiation | 10 | 2016 | 461 | 0.740 |
Why?
|
| Bone Marrow Transplantation | 3 | 2013 | 68 | 0.700 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2013 | 14 | 0.670 |
Why?
|
| Interferon-beta | 7 | 2013 | 19 | 0.660 |
Why?
|
| Adipocytes | 5 | 2016 | 69 | 0.590 |
Why?
|
| Inflammation | 3 | 2012 | 506 | 0.580 |
Why?
|
| Glioma | 6 | 2016 | 137 | 0.560 |
Why?
|
| Adenoviridae | 10 | 2013 | 68 | 0.540 |
Why?
|
| Flow Cytometry | 9 | 2014 | 184 | 0.530 |
Why?
|
| Green Fluorescent Proteins | 4 | 2013 | 70 | 0.530 |
Why?
|
| Osteoblasts | 3 | 2019 | 43 | 0.500 |
Why?
|
| Adipose Tissue | 4 | 2013 | 320 | 0.480 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 93 | 0.470 |
Why?
|
| Genetic Vectors | 9 | 2012 | 108 | 0.450 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2017 | 106 | 0.450 |
Why?
|
| Humans | 54 | 2020 | 32282 | 0.440 |
Why?
|
| Cell Proliferation | 11 | 2019 | 603 | 0.410 |
Why?
|
| Leukemia | 3 | 2010 | 38 | 0.390 |
Why?
|
| Gene Transfer Techniques | 4 | 2011 | 60 | 0.390 |
Why?
|
| Glioblastoma | 4 | 2020 | 159 | 0.370 |
Why?
|
| Cell Lineage | 4 | 2016 | 65 | 0.370 |
Why?
|
| Apoptosis | 10 | 2015 | 375 | 0.360 |
Why?
|
| Brain Neoplasms | 7 | 2016 | 637 | 0.360 |
Why?
|
| Female | 26 | 2020 | 19945 | 0.360 |
Why?
|
| Xenograft Model Antitumor Assays | 12 | 2019 | 114 | 0.350 |
Why?
|
| Mesoderm | 2 | 2009 | 12 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 131 | 0.340 |
Why?
|
| Nanoparticles | 3 | 2016 | 52 | 0.340 |
Why?
|
| Cell Migration Assays | 1 | 2011 | 2 | 0.340 |
Why?
|
| Cell Separation | 7 | 2016 | 89 | 0.330 |
Why?
|
| Mice, Nude | 14 | 2020 | 285 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 258 | 0.330 |
Why?
|
| Neoplastic Stem Cells | 4 | 2013 | 96 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 7 | 2016 | 792 | 0.310 |
Why?
|
| T-Lymphocytes | 2 | 2009 | 140 | 0.310 |
Why?
|
| Phenotype | 5 | 2017 | 622 | 0.310 |
Why?
|
| Chemotaxis | 1 | 2009 | 20 | 0.310 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 221 | 0.300 |
Why?
|
| Neoplasm Proteins | 6 | 2020 | 146 | 0.300 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 1083 | 0.300 |
Why?
|
| Transduction, Genetic | 10 | 2012 | 39 | 0.300 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2012 | 89 | 0.290 |
Why?
|
| Graft Survival | 1 | 2009 | 293 | 0.280 |
Why?
|
| Neoplasm Transplantation | 7 | 2013 | 73 | 0.270 |
Why?
|
| Hyaluronic Acid | 3 | 2016 | 51 | 0.270 |
Why?
|
| Luminescent Proteins | 3 | 2013 | 25 | 0.260 |
Why?
|
| Cells, Cultured | 9 | 2013 | 839 | 0.260 |
Why?
|
| Culture Media, Conditioned | 8 | 2019 | 50 | 0.260 |
Why?
|
| Graft vs Host Disease | 1 | 2007 | 39 | 0.250 |
Why?
|
| Immunohistochemistry | 7 | 2014 | 545 | 0.250 |
Why?
|
| Positron-Emission Tomography | 3 | 2020 | 171 | 0.250 |
Why?
|
| Mice, Transgenic | 4 | 2016 | 257 | 0.250 |
Why?
|
| Infrared Rays | 2 | 2016 | 17 | 0.240 |
Why?
|
| Luminescent Measurements | 3 | 2018 | 16 | 0.240 |
Why?
|
| Stem Cells | 2 | 2007 | 321 | 0.230 |
Why?
|
| Mice, SCID | 9 | 2012 | 73 | 0.230 |
Why?
|
| Cord Blood Stem Cell Transplantation | 3 | 2010 | 7 | 0.230 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2016 | 65 | 0.230 |
Why?
|
| Signal Transduction | 4 | 2018 | 727 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Oligopeptides | 4 | 2010 | 49 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Fluorescent Dyes | 2 | 2015 | 52 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Models, Biological | 3 | 2017 | 408 | 0.200 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 222 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Interleukin-6 | 3 | 2015 | 224 | 0.190 |
Why?
|
| Cell Division | 5 | 2012 | 92 | 0.190 |
Why?
|
| Thymidine Kinase | 3 | 2012 | 5 | 0.190 |
Why?
|
| Omentum | 2 | 2013 | 25 | 0.190 |
Why?
|
| Endothelial Cells | 4 | 2020 | 193 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 381 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2013 | 60 | 0.180 |
Why?
|
| Neoplasms, Experimental | 2 | 2020 | 33 | 0.180 |
Why?
|
| Ganciclovir | 3 | 2012 | 23 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 595 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Transgenes | 4 | 2010 | 46 | 0.170 |
Why?
|
| Gelatinases | 1 | 2020 | 1 | 0.160 |
Why?
|
| Transplantation, Heterologous | 6 | 2012 | 109 | 0.160 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 19 | 0.160 |
Why?
|
| Carcinoma | 2 | 2012 | 92 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 30 | 0.160 |
Why?
|
| Cell Communication | 2 | 2019 | 37 | 0.160 |
Why?
|
| Trauma, Nervous System | 1 | 2020 | 9 | 0.160 |
Why?
|
| Lung Neoplasms | 3 | 2010 | 423 | 0.150 |
Why?
|
| Erectile Dysfunction | 1 | 2020 | 69 | 0.150 |
Why?
|
| Monocytes | 3 | 2016 | 141 | 0.150 |
Why?
|
| Receptor, TIE-2 | 2 | 2016 | 2 | 0.150 |
Why?
|
| Placenta | 1 | 2020 | 74 | 0.150 |
Why?
|
| Membrane Proteins | 1 | 2020 | 243 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 3 | 2015 | 23 | 0.140 |
Why?
|
| Extracellular Matrix | 2 | 2013 | 256 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2013 | 299 | 0.140 |
Why?
|
| Breast | 3 | 2019 | 63 | 0.140 |
Why?
|
| Feedback, Physiological | 1 | 2018 | 11 | 0.140 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2016 | 23 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2018 | 12 | 0.140 |
Why?
|
| Oncolytic Virotherapy | 2 | 2009 | 16 | 0.140 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 37 | 0.140 |
Why?
|
| Male | 13 | 2020 | 19441 | 0.130 |
Why?
|
| Norepinephrine | 1 | 2018 | 101 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 70 | 0.130 |
Why?
|
| Mucous Membrane | 1 | 2017 | 27 | 0.130 |
Why?
|
| Contrast Media | 2 | 2016 | 136 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 117 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 95 | 0.130 |
Why?
|
| Cell Line | 4 | 2012 | 454 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 246 | 0.130 |
Why?
|
| Bioengineering | 1 | 2017 | 77 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 95 | 0.130 |
Why?
|
| Organoids | 1 | 2017 | 99 | 0.120 |
Why?
|
| Pericytes | 1 | 2016 | 32 | 0.120 |
Why?
|
| Fluorescence | 1 | 2016 | 22 | 0.120 |
Why?
|
| Leukemia, Myeloid | 3 | 2010 | 26 | 0.120 |
Why?
|
| Benzamides | 2 | 2014 | 60 | 0.120 |
Why?
|
| Exosomes | 1 | 2016 | 43 | 0.120 |
Why?
|
| Transfection | 4 | 2010 | 204 | 0.120 |
Why?
|
| Materials Testing | 1 | 2016 | 89 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 33 | 0.110 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 219 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 47 | 0.110 |
Why?
|
| Indocyanine Green | 1 | 2015 | 14 | 0.110 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2014 | 1 | 0.110 |
Why?
|
| Pyridines | 1 | 2014 | 79 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2016 | 181 | 0.100 |
Why?
|
| Cell Growth Processes | 2 | 2010 | 10 | 0.100 |
Why?
|
| Fluorouracil | 2 | 2017 | 79 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Macrophages | 1 | 2015 | 207 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 65 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2003 | 19 | 0.100 |
Why?
|
| Arabinofuranosyluracil | 2 | 2011 | 2 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2013 | 499 | 0.100 |
Why?
|
| Herpesvirus 1, Human | 2 | 2011 | 8 | 0.100 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2010 | 13 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 196 | 0.100 |
Why?
|
| Cell Culture Techniques | 2 | 2010 | 170 | 0.090 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2012 | 1 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 63 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2013 | 68 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 180 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2012 | 29 | 0.090 |
Why?
|
| Gangliosides | 1 | 2012 | 7 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 53 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 520 | 0.090 |
Why?
|
| Osteocytes | 1 | 2012 | 4 | 0.090 |
Why?
|
| Retroviridae | 2 | 2012 | 15 | 0.090 |
Why?
|
| Antigens, CD34 | 2 | 2009 | 48 | 0.090 |
Why?
|
| Regeneration | 1 | 2013 | 178 | 0.090 |
Why?
|
| Chondrocytes | 1 | 2012 | 70 | 0.090 |
Why?
|
| Fetal Blood | 2 | 2009 | 34 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 49 | 0.090 |
Why?
|
| Amniotic Fluid | 1 | 2011 | 85 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2018 | 111 | 0.080 |
Why?
|
| Cell Survival | 5 | 2011 | 288 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2011 | 27 | 0.080 |
Why?
|
| Neuropilin-1 | 1 | 2010 | 12 | 0.080 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2010 | 3 | 0.080 |
Why?
|
| Umbilical Cord | 1 | 2010 | 8 | 0.080 |
Why?
|
| Growth Inhibitors | 1 | 2010 | 7 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2008 | 48 | 0.080 |
Why?
|
| Genetic Engineering | 2 | 2007 | 22 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2010 | 21 | 0.080 |
Why?
|
| Lymphoma | 1 | 2010 | 37 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 28 | 0.080 |
Why?
|
| Myocardium | 1 | 2011 | 184 | 0.080 |
Why?
|
| Regenerative Medicine | 1 | 2013 | 217 | 0.080 |
Why?
|
| Disease Progression | 2 | 2009 | 591 | 0.080 |
Why?
|
| Immunosuppression | 1 | 2010 | 118 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 16 | 0.080 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 431 | 0.080 |
Why?
|
| Viscera | 1 | 2009 | 13 | 0.080 |
Why?
|
| Coculture Techniques | 4 | 2016 | 78 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 5 | 2012 | 164 | 0.080 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 28 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 907 | 0.080 |
Why?
|
| Kidney | 1 | 2013 | 521 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 14 | 0.070 |
Why?
|
| Multipotent Stem Cells | 1 | 2009 | 16 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 189 | 0.070 |
Why?
|
| Peptide Library | 2 | 2010 | 5 | 0.070 |
Why?
|
| Fetal Stem Cells | 1 | 2008 | 10 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 96 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2014 | 113 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 33 | 0.070 |
Why?
|
| Mice, Inbred AKR | 1 | 2007 | 6 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2007 | 19 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 36 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 466 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 45 | 0.060 |
Why?
|
| Mice, Inbred NOD | 3 | 2012 | 26 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 242 | 0.060 |
Why?
|
| Nitrophenols | 1 | 2006 | 2 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 158 | 0.060 |
Why?
|
| Biphenyl Compounds | 1 | 2006 | 21 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 150 | 0.060 |
Why?
|
| Capsid | 1 | 2006 | 8 | 0.060 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2006 | 12 | 0.060 |
Why?
|
| Chromatography, Gel | 1 | 2006 | 16 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 86 | 0.060 |
Why?
|
| raf Kinases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cytokines | 1 | 2007 | 237 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 89 | 0.060 |
Why?
|
| Antigens | 2 | 2016 | 34 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 38 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 893 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 113 | 0.050 |
Why?
|
| Genes, Reporter | 3 | 2011 | 41 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2017 | 132 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2006 | 211 | 0.050 |
Why?
|
| Neovascularization, Physiologic | 2 | 2016 | 114 | 0.050 |
Why?
|
| Telomerase | 1 | 2004 | 20 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 18 | 0.050 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2003 | 20 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 854 | 0.050 |
Why?
|
| Brain | 1 | 2010 | 965 | 0.050 |
Why?
|
| Time Factors | 4 | 2011 | 2205 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 203 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2003 | 5 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 78 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2003 | 12 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 215 | 0.050 |
Why?
|
| Melanoma | 1 | 2004 | 166 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2002 | 9 | 0.050 |
Why?
|
| Rats | 2 | 2020 | 1895 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2002 | 58 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.050 |
Why?
|
| Acute Disease | 3 | 2010 | 253 | 0.040 |
Why?
|
| Hypogastric Plexus | 1 | 2020 | 8 | 0.040 |
Why?
|
| Rats, Nude | 1 | 2020 | 48 | 0.040 |
Why?
|
| Penile Erection | 1 | 2020 | 31 | 0.040 |
Why?
|
| RNA Interference | 2 | 2010 | 78 | 0.040 |
Why?
|
| Macaca mulatta | 2 | 2012 | 340 | 0.040 |
Why?
|
| Pelvis | 1 | 2020 | 67 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2020 | 85 | 0.040 |
Why?
|
| Bone Matrix | 1 | 2019 | 2 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2019 | 41 | 0.040 |
Why?
|
| Antiviral Agents | 2 | 2012 | 107 | 0.040 |
Why?
|
| Peritoneum | 2 | 2012 | 32 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 239 | 0.040 |
Why?
|
| Cell Death | 2 | 2010 | 79 | 0.040 |
Why?
|
| Receptor, trkB | 1 | 2018 | 3 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2018 | 12 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2018 | 55 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 264 | 0.030 |
Why?
|
| U937 Cells | 2 | 2010 | 6 | 0.030 |
Why?
|
| Swine | 2 | 2011 | 228 | 0.030 |
Why?
|
| Peripheral Nerves | 1 | 2018 | 60 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 219 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2010 | 290 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 359 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 961 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2016 | 34 | 0.030 |
Why?
|
| Gene Expression | 2 | 2010 | 346 | 0.030 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Collagen | 1 | 2017 | 229 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 22 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2008 | 250 | 0.030 |
Why?
|
| Adult | 2 | 2016 | 9259 | 0.030 |
Why?
|
| Aged | 2 | 2016 | 10263 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 395 | 0.030 |
Why?
|
| Ligands | 2 | 2006 | 90 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 5 | 0.030 |
Why?
|
| Middle Aged | 2 | 2016 | 11851 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 23 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 34 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 74 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 81 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 109 | 0.030 |
Why?
|
| Chickens | 1 | 2013 | 36 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 149 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2004 | 193 | 0.020 |
Why?
|
| Pressure | 1 | 2013 | 69 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2013 | 10 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2012 | 5 | 0.020 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 27 | 0.020 |
Why?
|
| Sialyltransferases | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 18 | 0.020 |
Why?
|
| DNA Replication | 1 | 2012 | 33 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 79 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 83 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 22 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 7 | 0.020 |
Why?
|
| Lymphography | 1 | 2011 | 4 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 63 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 44 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 75 | 0.020 |
Why?
|
| Proteome | 1 | 2011 | 41 | 0.020 |
Why?
|
| K562 Cells | 1 | 2010 | 3 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 113 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 104 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 4 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2010 | 14 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 144 | 0.020 |
Why?
|
| Chondrogenesis | 1 | 2010 | 19 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 190 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 308 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 42 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 244 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2010 | 9 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2010 | 23 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 7 | 0.020 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2009 | 10 | 0.020 |
Why?
|
| Luminescent Agents | 1 | 2009 | 1 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2009 | 2 | 0.020 |
Why?
|
| Virus Replication | 1 | 2009 | 42 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2009 | 2 | 0.020 |
Why?
|
| Fluorine Radioisotopes | 1 | 2009 | 22 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 256 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 97 | 0.020 |
Why?
|
| Cathelicidins | 1 | 2009 | 1 | 0.020 |
Why?
|
| Chemotactic Factors | 1 | 2009 | 3 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2009 | 12 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2013 | 490 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 33 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 717 | 0.020 |
Why?
|
| Primates | 1 | 2009 | 128 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 89 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 1534 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 478 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 187 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2006 | 3 | 0.020 |
Why?
|
| Dimerization | 1 | 2006 | 30 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 12 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 112 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2006 | 110 | 0.020 |
Why?
|
| Piperazines | 1 | 2006 | 60 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 2006 | 12 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 2006 | 8 | 0.020 |
Why?
|
| Integrin alphaV | 1 | 2006 | 2 | 0.020 |
Why?
|
| Bacteriophages | 1 | 2006 | 2 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2006 | 8 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 112 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 120 | 0.020 |
Why?
|
| Dependovirus | 1 | 2006 | 18 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 1224 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 37 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 43 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2005 | 56 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 104 | 0.010 |
Why?
|
| Estradiol | 1 | 2005 | 139 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2004 | 10 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 99 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2004 | 14 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2004 | 4 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 38 | 0.010 |
Why?
|
| Cytarabine | 1 | 2004 | 59 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 2004 | 23 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 93 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2003 | 8 | 0.010 |
Why?
|
| Receptors, Leptin | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 75 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 60 | 0.010 |
Why?
|
| Tretinoin | 1 | 2003 | 33 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 43 | 0.010 |
Why?
|
| Leptin | 1 | 2003 | 61 | 0.010 |
Why?
|
| Ureter | 1 | 2004 | 39 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2004 | 80 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 477 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2003 | 45 | 0.010 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 27 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2003 | 97 | 0.010 |
Why?
|
| Idarubicin | 1 | 2002 | 8 | 0.010 |
Why?
|
| Blood Cells | 1 | 2002 | 9 | 0.010 |
Why?
|
| Topotecan | 1 | 2002 | 14 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2002 | 20 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 18 | 0.010 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2002 | 24 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 666 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 3900 | 0.010 |
Why?
|